ACACIA RESEARCH CORP (ACTG)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

0 100M 200M 300M Q3 '21: 29.2M Q4 '21: 88M Q1 '22: 95.8M Q2 '22: 95.1M Q3 '22: 109.4M Q4 '22: 59.2M Q1 '23: 60.5M Q2 '23: 51.7M Q3 '23: 45.9M Q4 '23: 125.1M Q1 '24: 134.6M Q2 '24: 152.6M Q3 '24: 165.8M Q4 '24: 122.3M Q1 '25: 222.4M Q2 '25: 247.8M Q3 '25: 283.9M Q4 '25: 285.2M Q1 '26: 215M Q2 '26: 278.4M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Gross Profit TTM

0 35M 70M 105M Q4 '22: 21.8M Q1 '23: 21.9M Q2 '23: 13.4M Q3 '23: 7.7M Q4 '23: 72.3M Q1 '24: 79.4M Q2 '24: 87.2M Q3 '24: 89.3M Q4 '24: 29.7M Q1 '25: 76.6M Q2 '25: 76.4M Q3 '25: 86.7M Q4 '25: 84.5M Q1 '26: 37.6M Q2 '26: 61.7M Q4 '22 Q2 '23 Q4 '23 Q2 '24 Q4 '24 Q2 '25 Q4 '25 Q2 '26

Operating Income TTM

-60M -40M -20M 0 20M 40M 60M Q3 '19: -5.9M Q4 '19: -23.4M Q1 '20: -20.1M Q2 '20: -22.9M Q3 '20: -20.5M Q4 '20: -19.5M Q1 '21: -21.6M Q2 '21: -13.2M Q3 '21: -23.2M Q4 '22: -40.1M Q1 '23: -40.9M Q2 '23: -47.8M Q3 '23: -49.6M Q4 '24: -32.9M Q1 '25: 7.5M Q2 '25: -161K Q3 '25: 3.7M Q4 '25: 6.4M Q1 '26: -40.3M Q2 '26: -19.4M Q4 '19 Q3 '20 Q2 '21 Q1 '23 Q4 '24 Q3 '25 Q2 '26

Net Income TTM

-180M -90M 0 90M 180M 270M Q3 '21: 25.2M Q4 '21: 149.2M Q1 '22: 240.4M Q2 '22: 159.2M Q3 '22: 97.6M Q4 '22: -127.2M Q1 '23: -44.5M Q2 '23: -1.8M Q3 '23: -28.2M Q4 '23: 67.1M Q1 '24: 57.4M Q2 '24: 67.8M Q3 '24: 52.1M Q4 '24: -36.1M Q1 '25: -11.6M Q2 '25: -6.4M Q3 '25: 4.8M Q4 '25: 23M Q1 '26: -17M Q2 '26: -13.7M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Cost of Revenue TTM

0 80M 160M 240M Q3 '21: 22.9M Q4 '21: 36.1M Q1 '22: 39.5M Q2 '22: 39.5M Q3 '22: 45.5M Q4 '22: 37.4M Q1 '23: 38.6M Q2 '23: 38.3M Q3 '23: 38.2M Q4 '23: 52.8M Q1 '24: 55.2M Q2 '24: 65.4M Q3 '24: 76.5M Q4 '24: 92.7M Q1 '25: 145.8M Q2 '25: 171.4M Q3 '25: 197.3M Q4 '25: 200.8M Q1 '26: 177.5M Q2 '26: 216.7M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Operating Cash Flow TTM

-60M -30M 0 30M 60M 90M Q3 '21: -32.8M Q4 '21: 13.3M Q1 '22: 16.3M Q2 '22: 2M Q3 '22: 7.3M Q4 '22: -37.3M Q1 '23: -38.5M Q2 '23: -38.9M Q3 '23: -41.7M Q4 '23: -22.5M Q1 '24: 36.7M Q2 '24: 67.6M Q3 '24: 65.8M Q4 '24: 50.1M Q1 '25: -2.3M Q2 '25: 31.7M Q3 '25: 41.8M Q4 '25: 75.2M Q1 '26: 76.2M Q2 '26: 30M Q4 '21 Q3 '22 Q2 '23 Q1 '24 Q4 '24 Q3 '25 Q2 '26

Free Cash Flow TTM

-180M -120M -60M 0 60M 120M 180M Q2 '20: -9M Q3 '20: 3.8M Q4 '20: -19.8M Q1 '21: -23.6M Q2 '21: -18.8M Q3 '21: -32.9M Q4 '21: 13.2M Q1 '22: 16.2M Q2 '22: 1.5M Q3 '22: 6.8M Q4 '22: -38.1M Q1 '23: -39.3M Q2 '23: -39.4M Q3 '23: -42M Q4 '23: -22.7M Q1 '24: 36.3M Q2 '24: -75.6M Q3 '24: -79.6M Q4 '24: -98.5M Q1 '25: -152.8M Q3 '20 Q2 '21 Q1 '22 Q4 '22 Q3 '23 Q2 '24 Q1 '25

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 35M 70M 105M Q2 '20: 49M Q3 '20: 90.6M Q4 '20: 49.2M Q1 '21: 48.6M Q2 '21: 83.1M Q3 '21: 93.1M Q1 '22: 46.5M Q2 '22: 44M Q3 '22: 71.2M Q1 '23: 89.1M Q2 '23: 58.4M Q3 '23: 99.1M Q1 '24: 99.7M Q2 '24: 100.1M Q3 '24: 99.9M Q1 '25: 97M Q2 '25: 96.2M Q3 '25: 96.4M Q1 '26: 96.5M Q2 '26: 98.1M Q3 '20 Q2 '21 Q2 '22 Q2 '23 Q2 '24 Q2 '25 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-2.40 -1.60 -0.80 0.00 0.80 1.60 2.40 Q4 '18: -2.10 Q1 '19: -1.38 Q2 '19: -0.93 Q3 '19: -0.41 Q4 '20: 1.98 Q1 '21: -1.07 Q2 '21: -0.93 Q3 '21: -0.39 Q3 '23: -0.96 Q4 '23: 0.35 Q1 '24: 0.42 Q2 '24: 0.70 Q3 '24: 0.59 Q4 '24: -0.35 Q1 '25: -0.10 Q2 '25: -0.05 Q3 '25: 0.06 Q4 '25: 0.22 Q1 '26: -0.19 Q2 '26: -0.16 Q1 '19 Q4 '20 Q3 '21 Q1 '24 Q4 '24 Q3 '25 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.